Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.73 EUR
Change Today -0.02 / -2.67%
Volume 435.0
TN7 On Other Exchanges
As of 5:47 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

titan pharmaceuticals inc (TN7) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/8/15 - €0.90
52 Week Low
11/19/14 - €0.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

titan pharmaceuticals inc (TN7) Related Businessweek News

No Related Businessweek News Found

titan pharmaceuticals inc (TN7) Details

Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company is developing Probuphine for the long term maintenance treatment of opioid dependence. Its Probuphine is designed to maintain a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment; and utilizes ProNeura, a novel, proprietary, and long-term drug delivery technology. The company’s ProNeura is also used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease. It is also developing Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.

13 Employees
Last Reported Date: 03/31/15
Founded in 1992

titan pharmaceuticals inc (TN7) Top Compensated Officers

President, Secretary, and Director
Total Annual Compensation: $300.0K
Executive Chairman and Member of Executive Co...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2014.

titan pharmaceuticals inc (TN7) Key Developments

Titan Pharmaceuticals Inc. Presents at BIO International Convention 2015, Jun-16-2015 04:15 PM

Titan Pharmaceuticals Inc. Presents at BIO International Convention 2015, Jun-16-2015 04:15 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Sunil Bhonsle, President, Secretary and Director.

Titan Pharmaceuticals Inc. Reports Positive Topline Results from the Phase 3 Double Blind, Double Dummy Clinical Study of Probuphine

Titan Pharmaceuticals Inc. reported positive topline results from the Phase 3 double blind, double dummy clinical study of Probuphine, the Company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. This study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints. It was conducted by Titan's commercialization and development partner Braeburn Pharmaceuticals and developed in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study. The subjects in this Phase 3 study were clinically stable patients receiving maintenance treatment with an approved sublingual dose of uprenorphine/naloxone at a daily dose of 8mg or less for at least three months prior to entering the trial. The study enrolled 177 subjects who were randomized to receive either the Probuphine implants or sublingual tablets, for a treatment period of six months. Subjects in one group received four Probuphine implants plus daily placebo sublingual tablets, and subjects in the second group received four placebo implants plus daily sublingual buprenorphine/naloxone tablets (8mg/day). The objective of the study was to show non-inferiority between the two treatment groups and the primary efficacy analysis was a non-inferiority comparison of the proportions of treatment responders in each group. A responder was defined as having at least four out of six months free of illicit opioids based on urine testing and subject self-report. Analyses conducted according to the pre-planned Statistical Analysis Plan indicate response rates of 96.4% for the Probuphine arm and 87.6% for the sublingual buprenorphine/naloxone arm. The two-sided 95% confidence interval (0.009, 0.167) of the treatment difference (Probuphine - Sublingual Buprenorphine/naloxone) was well above the minimum pre-defined successful margin for non-inferiority. The overall safety and tolerability profiles for each treatment group were also comparable. The implantation procedures were also generally well tolerated and comparable to observations from earlier studies with Probuphine. If approved by the FDA, Probuphine would be the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single procedure. Probuphine was developed using Titan's proprietary platform technology, ProNeura, a non-biodegradable drug delivery implant designed to provide continuous, long- term steady state levels of medication in the blood. It is administered in a short subdermal insertion procedure in a physician's office, and removed similarly at the end of the treatment period.

Titan Pharmaceuticals Inc. - Special Call

To review results from phase 3 study of probuphine for opioid addiction


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TN7:GR €0.73 EUR -0.02

TN7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $63.07 USD -1.70
Reckitt Benckiser Group PLC 5,526 GBp -28.00
View Industry Companies

Industry Analysis


Industry Average

Valuation TN7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.8x
Price/Book 19.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TITAN PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at